

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ISPH-0774**

Inventors: **Baker et al.**

Serial No.: **Not Yet Assigned**

Filing Date: **Herewith**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Title: **Antisense Modulation of Urokinase Plasminogen Activator Expression**

"Express Mail" Label No. **EL977826888US**
Date of Deposit September 19, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Sequence, P. O. Box 1450, Alexandria, VA 22313-1450.

By Jane Massey Licata
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(xx) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

() Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/821,972, filed March 30, 2001 for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: September 19, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. ISPH-0774	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Brenda F. Baker et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Andreasen et al., The plasminogen activation system in tumor growth, invasion, and metastasis, <i>Cell. Mol. Life Sci.</i> , 2000, 57:25-40.	
	AB	Engelhard, Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors, <i>Cancer Control</i> , 1998, 5:163-170	
	AC	Haeckel et al., Antisense inhibition of urokinase: Effect on malignancy in a human osteosarcoma cell line, <i>Int. J. Cancer</i> , 1998, 77:153-160	
	AD	McGuire et al., Inhibition of urokinase synthesis and cell surface binding alters the motile behavior of embryonic endocardial-derived mesenchymal cells in vitro, <i>Development</i> , 1993, 118:931-939	
	AE	Morrissey et al., Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor, <i>Clin. Exp. Metastasis</i> , 1999, 17:77-85	
	AF	Parry et al., Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues, <i>Trends Biochem. Sci.</i> , 2000, 25:53-59.	
	AG	Riccio et al., The human urokinase-plasminogen activator gene and its promoter, <i>Nucleic Acids Res.</i> , 1985, 13:2759-2771	
	AH	Schmitt et al., Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy, <i>Thromb. Haemost.</i> , 1997, 78:285-296	
	AI	Werb, ECM and cell surface proteolysis: regulating cellular ecology, <i>Cell</i> , 1997, 91:439-442.	
	AJ	Wilhelm et al., Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice, <i>Clin. Exp. Metastasis</i> , 1995, 13:296-302	
EXAMINER		DATE CONSIDERED	

Form PTO-1449. Modified		Docket No. ISPH-0774	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Brenda F. Baker et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AK	Wilson et al., Role of urokinase and its receptor in basal and stimulated colonic epithelial cell migration in vitro, Gut, 2000, 47:105-111	
	AL	Yu et al., Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes, Cancer Res., 1990, 50:7623-7633	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. ISPH-0774	Serial No.
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Brenda F. Baker et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date	Group

U. S. PATENT DOCUMENTS

Examiner's Initial	Document No.	Date	Name	Class	Subclass
AA	5,552,390	9/3/1996	Scholar et al.	514	44
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					
AK					
AL					
AM					
AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial	Document No.	Date	Country	Translation YES	Translation NO
AO					
AP					
AQ					
AR					
AS					
AT					
AU					
AV					
AW					
AX					

EXAMINER DATE CONSIDERED